research Content validity of five single‐item instruments in adolescents with alopecia areata
The instruments are valid but don't fully capture the emotional impact on adolescents with alopecia areata.
Search
for
Sort by
Research
60-90 / 1000+ resultsresearch Real‐World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi‐Center Cohort Study
Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
research The most impactful aspects of living with alopecia areata among patients commencing systemic treatments: Evaluating patients’ perspectives to guide therapy
Facial hair loss and psychosocial issues are crucial in deciding treatment for alopecia areata.
research Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
research Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is effective long-term for treating alopecia areata in teens.
research Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast
Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.
research Long‐Term Real‐World Outcomes of Baricitinib in Severe Alopecia Areata: A 104‐Week Retrospective Analysis From a Single Institute
Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
research Baricitinib regrows hair in adolescents with alopecia areata
Baricitinib helps regrow hair in teens with severe alopecia areata.
research Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
research Race and Ethnicity Sub-Groups of Alopecia Areata Patients have Differing Clinical Characteristics: TARGET-DERM AA
Alopecia areata severity and symptoms vary by race and ethnicity.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
research Depression among Alopecia Areata Patients: Prevalence and associated factors in a Tunisian sample
Over half of alopecia areata patients in Tunisia experience depression, highlighting the need for psychological support.
research 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
research Ritlecitinib in severe alopecia areata: a profile of its use
Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
research The fate of non-scalp hair in alopecia areata universalis under baricitinib treatment: A real-world single-center experience
Baricitinib effectively promotes hair regrowth in both scalp and nonscalp areas for alopecia areata universalis patients.
research Efficacy of modern methods for assessing the severity of alopecia areata
The SBN system effectively assesses alopecia areata severity and predicts its course.
research 131 Patient experiences with alopecia areata: Sentiment analysis of survey responses
Alopecia areata causes negative emotions and stress due to hair loss and emotional triggers.
research Case report: Sequential therapy with dupilumab and baricitinib for severe alopecia areata with atopic dermatitis in children
Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.
research P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience
Baricitinib was effective and safe for severe hair loss treatment over 6 months.
research Signposts to the Promised Land in Alopecia Areata
Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.
research A CLINICAL STUDY OF ALOPECIA AREATA AND TO EVALUAT E OF THE EFFICACY OF 0.03% TOPICAL TACROLIMUS IN ITS TREATMENT
Topical tacrolimus is effective and safe for treating alopecia areata.
research Alopecia areata: Clinical presentation, diagnosis, and unusual cases
Alopecia areata is a hair loss condition that often starts before age 30 and can affect various body parts, with unpredictable hair regrowth chances.
research Alopecia areata - need for a revision in morphological classification and scoring
A new classification and scoring system is needed for alopecia areata to better assess severity.
research Successful treatment of alopecia areata‐associated trachyonychia with baricitinib
Baricitinib improved nail condition and hair regrowth in a patient with alopecia and nail abnormalities.
research Topical Bimatoprost (0.03%) Versus Topical Mometasone Furoate (0.1%) in Treatment of Alopecia Areata
Mometasone furoate cream was more effective than bimatoprost solution for treating hair loss from Alopecia Areata.
research British Association of Dermatologists’ guidelines for the management of alopecia areata 2012
Guidelines suggest various treatments for alopecia areata, but leaving it untreated is also an option as 80% cases may recover on their own.
research Frontal Fibrosing Alopecia in Men: A Review of the Literature
Frontal fibrosing alopecia in men is often misdiagnosed and needs better diagnostic criteria and treatments.
research Off-Label Use of Topical Minoxidil in Alopecia: A Review
Minoxidil helps treat eyebrow thinning, monilethrix, early hair loss, and shortens chemo-related hair loss.
research A qualitative phase I study protocol on developing patient-reported outcome measure for hair, scalp, eyebrows, eyelashes, and beard-related skin disorders
The goal is to create a tool for patients to report their experiences with various hair and scalp disorders.